Postoperative solitary liver metastasis from esophageal squamous cell carcinoma achieving a clinical complete response to chemotherapy with cisplatin and 5-fluorouracil followed by stereotactic body radiotherapy: A case report.
esophageal cancer
liver metastases
oligometastasis
oligorecurrence
stereotactic ablative radiotherapy
Journal
Molecular and clinical oncology
ISSN: 2049-9450
Titre abrégé: Mol Clin Oncol
Pays: England
ID NLM: 101613422
Informations de publication
Date de publication:
Jul 2021
Jul 2021
Historique:
received:
12
01
2021
accepted:
16
04
2021
entrez:
31
5
2021
pubmed:
1
6
2021
medline:
1
6
2021
Statut:
ppublish
Résumé
Treatment strategies for distant organ metastasis have changed markedly since the concept of oligometastasis was introduced. The perception that distant organ metastasis is a systemic disease and not eligible for local therapy is now a thing of the past. Therefore, the present report details a case of postoperative solitary liver metastasis from esophageal squamous cell carcinoma (ESCC), which achieved a clinical complete response to chemotherapy with cisplatin and 5-fluorouracil (5-FU) followed by stereotactic body radiotherapy (SBRT). A 76-year-old male patient underwent esophagectomy for lower thoracic ESCC. At 7 months after surgery, abdominal CT revealed a solitary hypovascular mass, 28 mm in size, in segment 7 of the liver. After three courses of chemotherapy with cisplatin and 5-FU, abdominal CT revealed that the liver mass had shrunk to 7 mm in size. SBRT was then administered with a 6 MV X-ray beam generated by a linear accelerator. A total dose of 50 Gy was given in 5 fractions of 10 Gy to the liver mass. At 1 month after SBRT, abdominal CT revealed that the liver mass had disappeared. The patient received no further adjuvant chemotherapy and had no recurrence at 18 months after diagnosis of liver metastasis and 13 months after SBRT.
Identifiants
pubmed: 34055345
doi: 10.3892/mco.2021.2292
pii: MCO-0-0-02292
pmc: PMC8138851
doi:
Types de publication
Journal Article
Langues
eng
Pagination
130Informations de copyright
Copyright: © Fukuda et al.
Déclaration de conflit d'intérêts
The authors declare that they have no competing interests.
Références
World J Gastrointest Oncol. 2019 Sep 15;11(9):741-749
pubmed: 31558978
Esophagus. 2019 Jan;16(1):25-43
pubmed: 30171414
J Clin Oncol. 1995 Jan;13(1):8-10
pubmed: 7799047
Ann Surg Oncol. 2020 Mar;27(3):651-659
pubmed: 31898096
Eur J Cancer. 1997 Jul;33(8):1216-20
pubmed: 9301445
Lancet. 2013 Feb 2;381(9864):400-12
pubmed: 23374478
Eur J Cancer. 2009 Nov;45(17):2947-59
pubmed: 19773153
Dis Esophagus. 2014 Jan;27(1):36-41
pubmed: 23384275
JAMA Oncol. 2021 Jan 1;7(1):92-106
pubmed: 33237270
Ann Thorac Surg. 2018 Feb;105(2):357-362
pubmed: 29275824
Nat Rev Clin Oncol. 2014 Sep;11(9):549-57
pubmed: 24958182
Jpn J Clin Oncol. 1992 Jun;22(3):172-6
pubmed: 1518165
Ann Surg Oncol. 2011 Nov;18(12):3353-61
pubmed: 21537861
Surg Today. 2021 May;51(5):798-806
pubmed: 33130992
Radiother Oncol. 2021 Jan;154:201-206
pubmed: 32980382
J Clin Oncol. 2009 Apr 1;27(10):1572-8
pubmed: 19255321
Dis Esophagus. 2015 Jul;28(5):483-7
pubmed: 24898890
J Clin Oncol. 2020 Sep 1;38(25):2830-2838
pubmed: 32484754
Esophagus. 2021 Jan;18(1):1-24
pubmed: 33047261
Lancet Oncol. 2020 Jan;21(1):e18-e28
pubmed: 31908301